Globus Medical (GMED) Tops Q2 EPS by 7c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Globus Medical (GMED) PT Raised to $78 at RBC Capital
August 7, 2024 7:00 AM EDTRBC Capital analyst Shagun Singh raised the price target on Globus Medical (NYSE: GMED) to $78.00 (from $76.00) while maintaining a Outperform rating.
The analyst comments "GMED issued Q2 results, delivering an upside surprise of 2% and 11% in sales and EPS, respectively. This was the third consolidated... More
Globus Medical (GMED) PT Raised to $79 at Truist Securities
August 7, 2024 6:08 AM EDTTruist Securities analyst Richard Newitter raised the price target on Globus Medical (NYSE: GMED) to $79.00 (from $78.00) while maintaining a Hold rating.
The analyst comments "GMED delivered a good qtr, post-deal integration with dissynergies no worse than feared, and mgmt appears on... More
Globus Medical (GMED) PT Raised to $100 at Roth/MKM
August 7, 2024 5:17 AM EDTRoth/MKM analyst Jason Wittes raised the price target on Globus Medical (NYSE: GMED) to $100.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "GMED reported 2Q24 revenues of $629.7 million compared to consensus of $615.3 million, and adjusted EPS of $0.75 compared to consensus of $0.68. Adjusted... More
